Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by eSnowdenon May 04, 2018 7:07pm

211 Views

Post# 27985846

RE:RE:RE:May 2nd conference call

Apicore sold for $105 million USD to Mylan labs in the US. After the debt is paid, that leaves nearly $60 million USD. The current valuation of Medicure is $75million USD...so essentially the co. is valued at $15million. I applaud Albert for getting the co. out of bankruptcy, but with declining revenues & questionable growth ahead, I'm a bit worried about future prospects for the co. In addition, published employee reviews concerning MPH are not favorable. I hope this co. can be turned around.

Bullboard Posts

Twelve Labs partners with AWS to revolutionize video search with AI